DO CD34(+) CELL COUNTS PREDICT HEMATOPOIETIC RECOVERY AFTER AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)

被引：1
作者：
MIJOVIC, A
MUFTI, GJ
机构：
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1995年 / 89卷 / 01期
关键词：
D O I：
10.1111/j.1365-2141.1995.tb08939.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：226 / 227
页数：2
相关论文
共 50 条
[41]   Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation [J].
Kaffenberger, Benjamin H. ;
Wong, Henry K. ;
Jarjour, Wael ;
Andritsos, Leslie A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (03) :489-492
[42]   Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation [J].
Frère, P ;
Pereira, M ;
Fillet, G ;
Beguin, Y .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (02) :102-108
[43]   Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery [J].
Remes, K ;
Matinlauri, I ;
Grenman, S ;
Itala, M ;
Kauppila, M ;
Pelliniemi, TT ;
Salminen, E ;
Vanharanta, R ;
Rajamaki, A .
JOURNAL OF HEMATOTHERAPY, 1997, 6 (01) :13-19
[44]   Relationship of CD34(+) cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation [J].
Kiss, JE ;
Rybka, WB ;
Winkelstein, A ;
deMagalhaesSilverman, M ;
Lister, J ;
DAndrea, P ;
Ball, ED .
BONE MARROW TRANSPLANTATION, 1997, 19 (04) :303-310
[45]   Absence of a CD34− hematopoietic precursor population in recipients of CD34+ stem cell transplantation [J].
S Kato ;
K Ando ;
Y Nakamura ;
Y Muguruma ;
T Sato ;
H Yabe ;
M Yabe ;
K Hattori ;
Y Yasuda ;
T Hotta .
Bone Marrow Transplantation, 2001, 28 :587-595
[46]   Selection and expansion of peripheral blood CD34(+) cells in autologous stem cell transplantation for breast cancer [J].
Williams, SF ;
Lee, WJ ;
Bender, JG ;
Zimmerman, T ;
Swinney, P ;
Blake, M ;
Carreon, J ;
Schilling, M ;
Smith, S ;
Williams, DE ;
Oldham, F ;
VanEpps, D .
BLOOD, 1996, 87 (05) :1687-1691
[47]   Relationship of CD 34+cell dose to hematopoietic recovery and transfusion requirements following autologous peripheral blood stem cell transplantation (PBSCT). [J].
Anguita, J ;
Gómez-Pineda, A ;
Ballesteros, M ;
Serrano, D ;
Diez-Martín, JL ;
Pintado, T .
BLOOD, 1999, 94 (10) :334B-334B
[48]   High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer [J].
Braunschweig, I ;
Mirza, NQ ;
Rondon, G ;
Lauppe, J ;
Mehra, R ;
Gajewski, J ;
Körbling, M ;
Huh, YO ;
Geisler, D ;
Gee, AP ;
Champlin, R ;
Przepiorka, D .
CYTOTHERAPY, 2000, 2 (02) :105-110
[49]   Effects of CD34(+) selection and T cell immunodepletion on cord blood hematopoietic progenitors: Relevance to stem cell transplantation [J].
Laver, J ;
Traycoff, CM ;
AbdelMageed, A ;
Gee, A ;
Lee, C ;
Turner, C ;
Srour, EF ;
Abboud, M .
EXPERIMENTAL HEMATOLOGY, 1995, 23 (14) :1492-1496
[50]   Plerixafor approved for autologous hematopoietic stem-cell transplantation [J].
Traynor, Kate .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (02) :112-112
12345